Zim Laboratories Peer Comparison

NSE: ZIMLAB | BSE: 541400

₹122.69

₹-2.77 (-2.21%)

As on 31-Aug-2026IST

Market cap

₹663 Cr

Revenue (TTM)

₹397 Cr

P/E Ratio

179.5

P/B Ratio

2.3

Div. Yield

0 %

Edit

	Zim Laboratories	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	663	21,441	19,134	17,987	17,427
Revenue (₹ Cr)	397	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	3.70	735.15	678.07	666.92	169.62
Net Margin (%)	0.91	26.88	28.10	20.60	6.90
RoE (%)	1.35	19.16	19.73	18.75	20.76
Price to Earnings	179.51	29.17	28.76	27.93	102.74
Price-To-Book	2.28	4.86	5.08	4.45	19.27

Income Statement (₹ Cr)

	Zim Laboratories	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	374.40	2,519.65	1,937.47	2,893.64	2,275.58
Total Income	385.78	2,707.60	2,033.90	2,912.00	2,304.07
Total Expenditure	344.39	1,615.47	1,290.54	1,876.44	2,013.55
EBITDA	30.01	904.18	646.93	1,017.20	262.03
Depreciation	19.98	57.73	65.96	315.46	28.58
EBIT	10.03	846.45	580.97	701.74	233.45
Interest	13.20	9.57	0.61	231.29	4.49
Other Income	11.38	187.95	96.43	18.36	28.49
Exceptional Items	--	-49.16	--	--	-5.25
Profit before Tax	8.21	975.67	676.78	488.87	252.20
Provision for Tax	2.37	253.24	135.69	114.20	64.68
Profit after Tax	5.84	722.43	541.09	374.67	187.52

	Zim Laboratories	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	296.15	4,202.90	2,850.49	2,854.36	872.79
Minority Interest	0.00	--	35.90	417.40	--
Non-Current Liabilities	52.38	19.19	13.24	2,100.97	394.49
Current Liabilities	191.22	627.48	305.99	1,489.55	1,109.50
Total Liabilities	539.75	4,921.88	3,207.85	6,862.28	2,414.58

	Zim Laboratories	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	263.12	1,046.35	1,071.67	5,531.13	509.16
Current Assets	276.63	3,803.22	2,133.95	1,331.15	1,859.88
Total Assets	539.75	4,921.88	3,207.85	6,862.28	2,414.58
Total Debt*	122.82	2.50	0.55	2,421.66	0.00
Net Current Assets	85.42	3,175.74	1,827.96	-158.40	750.38
Contingent Liabilities	10.10	370.49	0.64	64.29	121.23

	Zim Laboratories	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	49.53	967.57	432.37	1,065.01	-15.14
Cash Flow from Investing Activities	-56.35	-561.67	-334.73	-79.97	18.69
Cash from Financing Activities	28.19	-798.31	-38.32	-881.32	-91.97
Net Cash Inflow / Outflow	21.37	-392.41	59.32	103.72	-88.42

	Zim Laboratories	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	5.47	23.39	26.22	13.59	31.24
ROE (%)	2.14	17.16	21.72	13.81	23.02
ROA (%)	1.15	14.91	18.37	5.48	8.90
EBIT Margin (%)	11.06	43.34	38.37	35.79	12.77
Net Margin (%)	1.51	26.68	26.60	12.87	8.14
Cash Profit Margin (%)	6.90	29.72	31.33	23.22	9.47

	Zim Laboratories	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	-1.22	10.45	14.37	44.02	32.59
EBIT Growth (%)	-16.40	19.68	20.21	48.22	-1.38
Net Profit Growth (%)	-52.01	-5.88	17.27	-5.65	62.02
EPS Growth (%)	-56.29	-5.88	17.25	-10.39	62.02
Book Value Growth (%)	17.07	-0.34	23.77	10.19	13.51

	Zim Laboratories	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	54.87	29.89	28.38	54.83	103.45
Price / Book Value	1.09	5.14	5.52	6.78	22.39
Dividend Yield (%)	0.00	1.59	0.30	0.52	0.46
EV/EBITDA	9.66	16.93	19.78	20.75	65.23
Market Cap (₹ Cr)	320.30	21,592.90	15,219.80	19,292.77	19,398.64

	Zim Laboratories	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.42	0.00	0.00	0.85	0.00
Short term debt to equity ratio	0.21	0.00	0.00	0.14	--
Current Ratio	1.45	6.06	6.97	0.89	1.68
Quick Ratio	0.96	5.31	5.88	0.67	0.75
Interest Coverage	1.62	102.95	1,110.48	3.11	57.17

	Zim Laboratories	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	29.12	7.22	32.65	15.85	9.39
Asset Turnover	0.74	0.54	0.66	0.43	1.08
Receivable days	105.27	26.06	110.70	54.07	31.88
Inventory Days	87.86	65.95	65.86	32.16	126.03
Payable days	157.18	81.01	105.88	140.91	163.79
Cash Conversion Cycle	35.94	11.00	70.68	-54.68	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.